Pay in 4 interest-free payments of $7.40 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
ATTAIN-1 (NCT05869903) was a Phase III, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of orforglipron at various doses to placebo in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease, who did not have diabetes
This outperformed diet alone and high-protein diet alone
Patients enrolled in Medicare who are diagnosed with obesity and related comorbidities will have a co-pay of $50 per month for Wegovy and Zepbound
People expect to feel better, so they convince themselves they do
Click here to get a demo of our full platform and coverage
Tune in for clinical pearls like the kill and spill analogy of thyroid antibodies, how TSH acts like a whip, and why tracking individual trends matters more than fixed reference ranges
US$ 28.21
US$ 25.24
US$ 28.87
US$ 26.58
US$ 27.12
US$ 26.28
US$ 28.82
US$ 25.84
US$ 22.14
